Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380751
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-03-25
Brief Title:
Saruparib AZD5305 Plus Camizestrant Compared With CDK46 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive HER2-Negative IHC 0 1 2 ISH Non-amplified BRCA1 BRCA2 or PALB2m Advanced Breast Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Breast Cancer |
Keywords: